|
市場調査レポート
商品コード
1184237
創傷デブリードマンの世界市場規模、シェア、産業動向分析レポート:購入形態別(処方箋、市販、その他)、製品別、方法別、創傷タイプ別、最終用途別、地域別展望と予測、2022年~2028年Global Wound Debridement Market Size, Share & Industry Trends Analysis Report By Mode of Purchase (Prescription, Over The Counter and Others), By Product, By Method, By Wound Type, By End-use, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
創傷デブリードマンの世界市場規模、シェア、産業動向分析レポート:購入形態別(処方箋、市販、その他)、製品別、方法別、創傷タイプ別、最終用途別、地域別展望と予測、2022年~2028年 |
出版日: 2022年12月30日
発行: KBV Research
ページ情報: 英文 338 Pages
納期: 即納可能
|
創傷デブリードマンの世界市場規模は、2028年までに61億米ドルに達し、予測期間中にCAGR5.5%の市場成長率で上昇すると予測されています。
一般的に、創傷床をより良く整えるためには、DIMEの順番で4つのステップを踏みます。DIMEとは、Debridement of dead tissues、management of Infection and Inflammation、Moisture control、Epithelialization、Environmental assessmentの頭文字をとったものです。この4つのステップからなるDIMEは、慢性創傷の管理方法としてよく知られており、創傷治癒を促進するためのより良い包括的な経路を開始することが可能です。
デブリードマンは、再上皮化のための創床準備に不可欠な部分です。特に壊死した組織は細菌の重要な栄養源となるため、このような組織の除去が必要です。創傷部位でのバクテリアの増殖は、治癒プロセスを阻害します。さらに、壊死した組織は、物理的な障壁となって再上皮化を妨げ、それによって、適用された局所化合物が創床と直接接触することを妨げます。
肉芽組織の形成、血管新生、正常な細胞外マトリックス、表皮の再表皮形成もまた、壊死した組織によって妨げられます。さらに、壊死した組織は、創傷の重症度と範囲を正確に評価することができず、根底にある感染症を隠してしまうこともあります。
COVID-19影響分析
パンデミックは世界全体と創傷デブリードマン市場に悪影響を及ぼしたが、新興国や低開発国のヘルスケア分野ではより顕著な影響を与えました。手術を含む多くの医療行為がキャンセルされ、ほとんどの病院が収容能力を超えました。現地の製造業者にとっては、パンデミックによってさまざまな展望が開けました。しかし、国境を越えた輸送が制限された結果、多くの企業のサプライチェーンに影響を及ぼし続けました。また、創傷処置に使用される医療用品は、使用事例の増加により供給が制限されました。このため、多くの地域メーカーが需要に対応するために生産を拡大しました。
市場成長要因
研究開発活動の活発化
多くのメーカーは、創傷デブリードマンに関連するさまざまなプロセスやデバイスに先進技術を取り入れることに注力しています。このため、革新的な材料や手法の研究開発への投資が増加しています。その結果、陰圧治療や生物工学的治療など、現在最も使用されている治療法よりも優れた効果を発揮することを目的とした数多くの先進的治療法が開発されています。したがって、このような研究開発活動は治療の選択肢を増やし、創傷被覆除去材市場に有利な成長機会を提供することになります。
世界の糖尿病人口の増加
世界保健機関(WHO)と国際糖尿病連合(IDF)が実施した調査によると、糖尿病を患う人は約5億3,700万人に上るとされています。また、WHOの調査によると、糖尿病の発症年齢が45~64歳にシフトしており、この年齢層の人は糖尿病や慢性的な傷にかかるリスクが高いことが分かっています。さらに、現在の統計では、2030年までに発展途上国の方が先進国よりも糖尿病患者の数が多くなるとされています。
市場の抑制要因
外科手術用デブリードマンデバイスのコスト高
外科的デブリードマンデバイスや酵素を用いたデブリードマンデバイスのコストが高いため、中低所得国の多くはこれらの装置を利用しにくくなっています。また、新興経済諸国は交通事故や怪我の発生率が高いため、より多くの創傷管理製品やデバイスが必要とされています。しかし、外科手術や酵素を用いた創傷デブリードマンは、多くの人々にとって高価なものとなっています。さらに、医療費の高騰による困難さから、創傷デブリードマンはあまり使用されていません。
購入形態別の展望
創傷デブリードマン市場は、購入形態によって、処方箋、市販、その他に分けられます。処方箋セグメントは、2021年に創傷剥離剤市場で最も高い収益シェアを獲得しました。ライセンスを持つヘルスケア専門家が処方するデブライドメント製品に有利な償還政策が利用できるため、多くの人が創傷デブリードマン処置を進めることができるようになりました。これは、この処方箋セグメントの成長をもたらす主な要因です。
製品の展望
創傷デブリードマン市場は、製品別に、ゲル、軟膏・クリーム、手術用具、医療用ガーゼ、超音波装置、その他に分類されます。ジェルセグメントは、2021年の創傷剥離剤市場で大幅に成長しました。ゲルは、創傷周囲の湿潤環境を促進するため、透明なハイドロゲルは、壊死した組織やスロージー組織の治療に顕著に使用されています。これらは、出血の少なさ、炎症の少なさ、組織の安全な除去、死角の充填など多くの利点があるため、他の多くの製品よりも好まれています。
方法の概要
創傷デブリードマン市場は、方法によって、自己溶解法、酵素法、外科的方法、機械的方法、その他に分類されます。酵素法は、2021年の創傷デブリードマン市場において有望な成長率を獲得しました。このプロセスは、壊死した組織のみを除去する選択的な処置でもあり、時間がかかるプロセスです。タンパク質分解酵素であるコラゲナーゼを利用し、細菌、特にクロストリジウム菌をデブライドするものです。コラゲナーゼ酵素が壊死組織のコラーゲンを消化することで、組織の剥離が容易になります。
創傷タイプ別の展望
創傷の種類によって、創傷デブリードマン市場は褥瘡、糖尿病性足潰瘍、静脈性下腿潰瘍、熱傷、その他に区分されます。2021年の創傷デブリードマン市場では、褥瘡分野が顕著な成長率を記録しました。褥瘡(じょくそう)は床ずれとも呼ばれ、強い圧力がかかることで皮膚に発生するものです。長期間のベッド上での安静や病院での入院がPUの主な原因であり、一般的に、ほとんどの症例が老年人口に見られるとされています。
エンドユーザー向け製品
創傷デブリードマン市場は、エンドユーザーによって病院、在宅医療、その他に分類されます。病院セグメントは、2021年の創傷デブリードマン市場で最大の収益シェアを獲得しました。病院の数の増加と外科手術の採用の増加の両方が、このセグメントに成長を与える主な要因です。これは、平均入院率も上昇していることを意味します。
地域別の展望
創傷デブリードマン市場は、地域別では北米、欧州、アジア太平洋、LAMEAで分析されています。北米セグメントは、2021年の創傷デブリードマン市場で最大の収益シェアを獲得しました。同地域では、慢性創傷に対する意識の高まりと、整備されたヘルスケア施設が、創傷デブリードマン処置を選択する人を増やしている主な理由となっています。さらに、同地域では心臓手術や外傷治療が大幅に増加していることも、創傷デブリードマンの製品や施術に対する需要を高めています。
市場参入企業がとっている主な戦略は買収です。カーディナルマトリックスで提示された分析によると、ジョンソン&ジョンソン(エシコン社)が創傷剥離市場の前身です。3M Company、Medtronic PLC、Baxter International, Inc.などの企業は、Wound Debridement市場の主要な革新者の一部です。
List of Figures
The Global Wound Debridement Market size is expected to reach $6.1 billion by 2028, rising at a market growth of 5.5% CAGR during the forecast period.
Wound debridement is defined as the removal of damaged, dead, and infected tissue that has thickened, deformed to callus, or is nonviable. The removal of such tissues is necessary for increasing the healing capabilities of remaining healthy tissues. The main objective of wound debridement is to successfully remove all of the dead and damaged tissue from the wound bed.
This process of tissue removal can also be used to remove bioburden, biofilm, and senescent cells and needs to be conducted at each encounter. In the debridement process, a wound management process that is more than a decade old, the chronic wound bed is prepared to facilitate reepithelialization.
In general, four steps in the order of DIME are followed for better preparation of the wound bed. The acronym DIME stands for Debridement of dead tissues, management of Infection and Inflammation, Moisture control, Epithelialization and Environmental assessment. These four steps of DIME are a well-recognized approach to chronic wound management from which a better comprehensive pathway can be started to facilitate wound resolution.
Debridement is an essential part of wound bed preparation for reepithelialization. The removal of devitalized tissue, in particular, the necrotic tissues, is necessary as such tissues become a significant nutrient source for bacteria. The growth of bacteria at the wound site hinders the healing process. Additionally, devitalized tissue also disrupts reepithelialization by posing as a physical barrier for it, thereby preventing the direct contact of applied topical compounds with the wound bed.
Granulation tissue formation, angiogenesis, normal extracellular matrix, and epidermal resurfacing formations are also prevented by the necrotic tissue. Furthermore, necrotic tissue also contains the accurate assessment of the wound's severity and extent and may mask any underlying infections.
COVID-19 Impact Analysis
The pandemic had a negative impact on the entire world and the wound debridement market, with effects more pronounced in the healthcare sectors in emerging and underdeveloped nations. The forced cancellation of numerous medical treatments, including surgery, resulted in most hospitals reaching their maximum capacities. For local manufacturers, the pandemic opened up a wide range of prospects. However, significant businesses' supply chains continued to be impacted as a result of the limitations on transportation at international borders. In addition, medical supplies used in wound debridement were available in limited supply due to the increase in cases. This prompted many regional manufacturers to expand production to keep up with demand.
Market Growth Factors
Rising Research And Development Activities
The focus of many manufacturers is shifting to incorporate advanced technologies in the various processes and devices involved in wound debridement procedures. This has increased the number of investments in the R&D of innovative materials and methods. As a result, numerous advanced therapies have been developed that aim to provide better effects than the current most used therapies like negative pressure therapies and bioengineered & biological therapies. Hence, such R&D activities increase the number of options available for treatment and, therefore, provide lucrative growth opportunities for the wound debridement market.
Growing Proportion Of The Diabetic Population Throughout The World
According to studies conducted by the World Health Organization (WHO) and International Diabetes Federation (IDF), there are approximately 537 million people suffering from diabetes. The studies by WHO also stated that the age of diabetes' onset has shifted to the 45 - 64 age bracket, putting individuals in this age group at a higher risk of getting diabetes and chronic wounds. Additionally, the current statistics highlight that by the year 2030, developing countries will have a higher number of diabetics than developed nations.
Market Restraining Factors
High Costs Of Surgical Debridement Devices
The high cost of surgical and enzymatic debridement equipment decreases the accessibility of these devices for many low and middle-income nations. In addition, since developing economies have a higher incidence rate of road accidents and injuries, they need more wound management products and devices. But surgical and enzymatic wound debridement interventions have become expensive for many individuals. Additionally, less use of wound debridement devices takes place because of difficulties due to the rising cost of healthcare.
Mode of Purchase Outlook
Based on mode of purchase, the wound debridement market is divided into prescription, over the counter, and others. The prescription segment acquired the highest revenue share in the wound debridement market in 2021. The availability of favorable reimbursement policies for the debridement products prescribed by a licensed healthcare practitioner has allowed many to proceed with wound debridement procedures. This is the main factor that is responsible for the growth of this prescription segment.
Product Outlook
On the basis of product, the wound debridement market is categorized into gels, ointments & creams, surgical devices, medical gauzes, ultrasonic devices, and others. The gels segment witnessed a considerable growth rate in the wound debridement market in 2021. Gels promote a moist environment around the wound, and therefore, clear hydrogels are prominently used for treating necrotic and sloughy tissues. These are preferred over many other products because of many benefits like less bleeding, less inflammation, safe removal of tissues, and filling of dead space.
Method Outlook
Based on method, the wound debridement market is divided into autolytic, enzymatic, surgical, mechanical, and others. The enzymatic segment garnered a promising growth rate in the wound debridement market in 2021. This process is also a selective procedure that only removes necrotic tissue and is a slow process. It utilizes collagenase, a proteolytic enzyme, to debride bacteria, specifically, the Clostridium bacteria. The collagenase enzyme digests the collagen of the necrotic tissue, which facilitates the detachment of the tissue.
Wound Type Outlook
On the basis of wound type, the wound debridement market is segmented into pressure ulcers, diabetic foot ulcers, venous leg ulcers, burn wounds, and others. The pressure ulcers segment recorded a remarkable growth rate in the wound debridement market in 2021. Pressure ulcers (Pus) are also referred to as bed sores and are caused on the skin because of intense pressure. Long-term bed rests and hospital stays are prominent causes of PUs, and generally, most cases are seen among the geriatric population.
End-Use Outlook
Based on end-use, the wound debridement market is fragmented into hospitals, homecare, and others. The hospital segment acquired the largest revenue share in the wound debridement market in 2021. Both the growing hospitals' number and the increase in the adoption of surgical procedures are the primary factors giving the segment its growth. This also implies that the average hospitalization rates have also increased.
Regional Outlook
On the basis of region, the wound debridement market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the maximum revenue share in the wound debridement market in 2021. The rising awareness about chronic wounds, along with the well-developed healthcare facilities in the region, are the main reasons that have prompted more people to opt for wound debridement procedures. In addition, the significant rise in heart operations and trauma care in the region have also increased the demand for wound debridement products and practices.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson (Ethicon, Inc.) is the forerunner in the Wound Debridement Market. Companies such as 3M Company, Medtronic PLC, and Baxter International, Inc. are some of the key innovators in Wound Debridement Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Strategies Deployed in Wound Debridement Market
Aug-2022: Medtronic came into partnership with BioIntelliSense, a US-based company, primarily into developing clinical intelligence platforms. The partnership involves granting US distribution rights of BioButton to Medtronic. BigButton is a medical device meant for remote monitoring.
Jun-2022: Smith+Nephew opened a new R & D center and manufacturing facility in Hull, United Kingdom. The new facility focuses on advanced wound management and aligns with Smith's devotion to the UK and advanced wound management.
Mar-2022: Convatec took over Triad Life Sciences, a US-based biotechnology company, primarily developing bioactive regenerative materials meant for hard-to-heal wounds, incisional wounds, and burns treatment. The acquisition reinforces Convatec's advanced wound care business by leveraging Triad's commercial competence.
Dec-2021: Baxter completed the acquisition of Hillrom, a US-based equipment company, primarily into providing medical supplies and hospital equipment. The acquisition enhances Baxter's capability to better serve clinicians, and patients worldwide, and further, opens up growth opportunities for Baxter.
Jul-2021: Baxter took over PerClot Polysaccharide Hemostatic System from CryoLife. PerClot Polysaccharide Hemostatic System is a medical device intended for controlling bleeding during surgeries. This acquisition aligns with Baxter's plan to take over technologies and products that enhance and expands its surgical products offerings and further complements Baxter's Seprafilm Adhesion Barrier acquisition. Additionally, this acquisition enables Baxter to enter the hemostatic powder segment.
Jun-2021: ConvaTec teamed up with RLS Global, a Sweden-based public company, primarily into developing and marketing biochemical products intended for diseases in dental and wound care. The collaboration involves granting global commercial rights for ChloraSolv in Europe to ConvaTec. ChloraSolv is a wound debrider meant for hard-to-heal wounds. The inclusion of ChloraSolv would add significant value to ConvTec's debridement solutions offerings.
Apr-2020: Medline partnered with BandGrip, a US-based medical device company, primarily into providing bandages, wound closures, etc. The partnership involves expanding the reach of BandGrips' patented micro-anchor skin closure technology. The micro-anchor skin technology benefits both surgeons and patients, as it is faster to apply and leaves less scar compared to traditional methods.
Jan-2020: Convatec introduced ConvaMax, a superabsorber wound dressing intended for wounds including pressure ulcers, leg ulcers, and diabetic foot ulcers. The new product offering complements Convatec's wound portfolio.
Oct-2019: 3M took over Acelity, a medical technology company primarily into advanced wound care. The acquisition combines two primary companies in their respective market segments, which benefits 3M's customers and shareholders and further advances 3M's market position in advanced wound care.
Jun-2019: Molnlycke partnered with Zuellig Pharma, a Hong Kong-based distributor of medical devices, pharmaceuticals, and clinical trial materials. The partnership involves offering advanced wound care solutions in South-East Asia, by leveraging Molnlycke competence in medical, sales, and marketing management in advanced wound care solutions and Zuellig's network.
May-2019: Ethicon, part of Johnson & Johnson medical devices company took over TachoSil Fibrin Sealant Patch from Takeda Pharmaceutical, a Japan-based pharmaceutical company. TachoSil Fibrin Sealant Patch is a surgical patch offering easy, rapid, and safe bleeding control meant for adult and pediatric patients where the bleeding is impractical and ineffective to control.
Apr-2019: Smith & Nephew took over Osiris Therapeutics, a US-based biotechnology company, specializing in orthopedics, wound care applications, and sport medicine products. The acquisition expands and strengthens Smith's product portfolio and advances its wound management business.
Market Segments covered in the Report:
By Mode of Purchase
By Product
By Method
By Wound Type
By End-use
By Geography
Companies Profiled
Unique Offerings from KBV Research